• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Basic Materials·TLDN.JK
Share

PT Teladan Prima Agro Tbk Stocks

IDR 525Last Updated 16.10.2026

Issuer Rating

5/7
Performance

Excellent

Risk

Considerable

Recommendation

Hold

Market Cap

IDR 407.82M

IDR 525
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Teladan Prima Agro Tbk, along with its subsidiaries, is a diversified agribusiness operating in palm oil plantation management, milling, and renewable energy production. The company cultivates a substantial 60,468 hectares of oil palm across East Kalimantan Province. From these extensive estates, including both its directly owned (nucleus) and partner (plasma) plantations, it processes fresh fruit bunches to yield crude palm oil and palm kernel. Additionally, PT Teladan Prima Agro Tbk generates green electricity by converting palm oil waste, supplying this power to external consumers. Established in 2004, the company's corporate headquarters are located in South Jakarta, Indonesia.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

19.10.2026 20:13

Silence Therapeutics shares soared 125%. Merck is acquiring the cancer therapy developer

19.10.2026 18:43

"A buying opportunity is emerging": Nasdaq jumped 1% after the sell-off

19.10.2026 18:30

Analysts see 35% upside in label maker Brady on data center demand and Honeywell deal

19.10.2026 18:09

Goldman names 23 'unloved' defensive stocks as tech falters

19.10.2026 16:08

Morning in New York: Looking for a Foothold Ahead of Tech Giants' Earnings Reports

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026